Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
4.41 +0.19 (+4.50%) 03/14/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 4.45 +0.04 (+0.91%) 18:25 ET
Quote Overview for Fri, Mar 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.07
Day High
4.48
Open 4.24
Previous Close 4.22 4.22
Volume 1,241,700 1,241,700
Avg Vol 1,218,375 1,218,375
Stochastic %K 12.79% 12.79%
Weighted Alpha -45.61 -45.61
5-Day Change -0.65 (-12.85%) -0.65 (-12.85%)
52-Week Range 4.07 - 19.71 4.07 - 19.71
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 307,099
  • Shares Outstanding, K 69,637
  • Annual Sales, $ 55,250 K
  • Annual Income, $ -334,330 K
  • EBIT $ -277 M
  • EBITDA $ -274 M
  • 60-Month Beta 0.63
  • Price/Sales 5.32
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 264.41% ( -64.37%)
  • Historical Volatility 104.75%
  • IV Percentile 99%
  • IV Rank 77.82%
  • IV High 328.78% on 03/13/25
  • IV Low 38.56% on 10/07/24
  • Put/Call Vol Ratio 1.88
  • Today's Volume 69
  • Volume Avg (30-Day) 621
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 11,216
  • Open Int (30-Day) 9,184

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.13
  • Number of Estimates 1
  • High Estimate -1.13
  • Low Estimate -1.13
  • Prior Year -1.42
  • Growth Rate Est. (year over year) +20.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.07 +8.35%
on 03/14/25
Period Open: 5.77
6.98 -36.82%
on 03/06/25
-1.36 (-23.57%)
since 02/14/25
3-Month
4.07 +8.35%
on 03/14/25
Period Open: 7.89
8.60 -48.72%
on 12/18/24
-3.48 (-44.11%)
since 12/13/24
52-Week
4.07 +8.35%
on 03/14/25
Period Open: 7.77
19.71 -77.63%
on 09/19/24
-3.36 (-43.24%)
since 03/14/24

Most Recent Stories

More News
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PHAT : 4.41 (+4.50%)
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

PHAT : 4.41 (+4.50%)
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,638.94 (+2.13%)
STOK : 8.60 (+6.04%)
ACAD : 17.50 (+4.29%)
PHAT : 4.41 (+4.50%)
BIIB : 139.44 (-0.39%)
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

PHAT : 4.41 (+4.50%)
Insider Purchase: Director at $PHAT (PHAT) Buys 12,500 Shares

FRANK KARBE, a director at $PHAT ($PHAT), bought 12,500 shares of the company on 12-13-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings...

PHAT : 4.41 (+4.50%)
Phathom Pharmaceuticals Submits Citizen Petition to Correct NCE Exclusivity Date for VOQUEZNA Tablets

Phathom Pharmaceuticals submitted a Citizen Petition to correct VOQUEZNA's NCE exclusivity expiration date to May 3, 2032.Quiver AI SummaryPhathom Pharmaceuticals has submitted a Citizen Petition to the...

PHAT : 4.41 (+4.50%)
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

PHAT : 4.41 (+4.50%)
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

PHAT : 4.41 (+4.50%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

PHAT : 4.41 (+4.50%)
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

PHAT : 4.41 (+4.50%)

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 4.98
2nd Resistance Point 4.73
1st Resistance Point 4.57
Last Price 4.41
1st Support Level 4.16
2nd Support Level 3.91
3rd Support Level 3.75

See More

52-Week High 19.71
Fibonacci 61.8% 13.74
Fibonacci 50% 11.89
Fibonacci 38.2% 10.04
Last Price 4.41
52-Week Low 4.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals